NASDAQ:VSAR

Versartis Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$1.19
0.00 (0.00 %)
(As of 10/15/2018)
Add
Compare
Today's Range
$1.18
$1.30
50-Day Range
$1.19
$1.19
52-Week Range
$1.14
$2.76
Volume349,963 shs
Average Volume479,436 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive VSAR News and Ratings via Email

Sign-up to receive the latest news and ratings for Versartis and its competitors with MarketBeat's FREE daily newsletter.


Versartis logo

About Versartis

Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VSAR
CUSIPN/A
Phone(936) 355-1910
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

0.69 out of 5 stars

Medical Sector

1293rd out of 2,045 stocks

Pharmaceutical Preparations Industry

562nd out of 771 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Versartis (NASDAQ:VSAR) Frequently Asked Questions

What stocks does MarketBeat like better than Versartis?

Wall Street analysts have given Versartis a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Versartis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Versartis' earnings last quarter?

Versartis, Inc. (NASDAQ:VSAR) released its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.69.
View Versartis' earnings history
.

Who are Versartis' key executives?

Versartis' management team includes the following people:
  • Gail Frances McIntyre, President, Chief Executive Officer & Director
  • Vinay Shah, Chief Financial Officer
  • Reshma Rangwala, Chief Medical Officer
  • Amy Franke, Vice President-Clinical Operations
  • Randy Anderson, Senior Vice President-Data Sciences

Who are some of Versartis' key competitors?

What other stocks do shareholders of Versartis own?

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

What is Versartis' stock price today?

One share of VSAR stock can currently be purchased for approximately $1.19.

What is Versartis' official website?

The official website for Versartis is www.versartis.com.

Where are Versartis' headquarters?

Versartis is headquartered at 1020 Marsh Rd, Menlo Park CA, 94025.

How can I contact Versartis?

Versartis' mailing address is 1020 Marsh Rd, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at (936) 355-1910 or via email at [email protected]


This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.